Scholarlink

<p>Approval of key drug classes has improved survival for patients with multiple myeloma (MM). However, most patients experience relapse or become refractory to these treatments, with retreatment having limited efficacy. Access to these key treatments varies widely across countries in Latin America (LATAM), which can lead to suboptimal clinical outcomes. This targeted literature review aimed to understand the epidemiology, burden of treatment, treatment sequencing and availability for MM in Argentina, Brazil, Chile, Colombia and Mexico, exploring recent literature on patient and clinical outcomes, and healthcare resource utilization (HCRU), in these countries. A literature search was conducted using four literature databases: PubMed, Embase, SciELO and LILACS (timeframe: 1 January 2014–1 November 2024). Articles of interest reported on patients with MM in the relevant LATAM countries focusing on epidemiology, any therapy for MM, treatment patterns, patient and clinical outcomes and HCRU. Findings were analyzed by geography, line of therapy and intervention, where data were available. Of 878 articles identified, 40 reported on outcomes of interest, which were mostly retrospective observational studies (<i>n</i> = 33). Epidemiology reported in these studies largely aligned with global data but varied across the countries. Treatments varied by country and healthcare settings, with newer drugs (such as lenalidomide, daratumumab, bortezomib) more likely to be used in private than public healthcare settings. Survival outcomes were variable and greater in private versus public healthcare settings. Adverse events were inconsistently reported across studies; generally, few events were serious or severe. HCRU was seldom reported. Overall, this review revealed a high variability in treatment patterns, limited availability of globally accepted standard of care treatments and disparate outcomes in countries in LATAM. Furthermore, we identified substantial gaps in the literature; filling these knowledge gaps in treatment utilization and outcomes may provide pathways to improving access for newer, more effective therapies, alleviating the substantial burden of MM in LATAM.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Burden of Treatment, Treatment Sequencing and Healthcare Resource Utilization in Multiple Myeloma in Latin America: A Targeted Literature Review

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月26日

查看全文
  • Cristian Maximiliano Seehaus,
  • Guillermina Remaggi,
  • Jayr Schmidt Filho,
  • Paola Ochoa,
  • Ricardo Bigni,
  • Roberto José Pessoa de Magalhães,
  • Ruddy Dalfeor,
  • Bhumika Aggarwal,
  • Claudia Soares,
  • Jacopo Bitetti

摘要

Approval of key drug classes has improved survival for patients with multiple myeloma (MM). However, most patients experience relapse or become refractory to these treatments, with retreatment having limited efficacy. Access to these key treatments varies widely across countries in Latin America (LATAM), which can lead to suboptimal clinical outcomes. This targeted literature review aimed to understand the epidemiology, burden of treatment, treatment sequencing and availability for MM in Argentina, Brazil, Chile, Colombia and Mexico, exploring recent literature on patient and clinical outcomes, and healthcare resource utilization (HCRU), in these countries. A literature search was conducted using four literature databases: PubMed, Embase, SciELO and LILACS (timeframe: 1 January 2014–1 November 2024). Articles of interest reported on patients with MM in the relevant LATAM countries focusing on epidemiology, any therapy for MM, treatment patterns, patient and clinical outcomes and HCRU. Findings were analyzed by geography, line of therapy and intervention, where data were available. Of 878 articles identified, 40 reported on outcomes of interest, which were mostly retrospective observational studies (n = 33). Epidemiology reported in these studies largely aligned with global data but varied across the countries. Treatments varied by country and healthcare settings, with newer drugs (such as lenalidomide, daratumumab, bortezomib) more likely to be used in private than public healthcare settings. Survival outcomes were variable and greater in private versus public healthcare settings. Adverse events were inconsistently reported across studies; generally, few events were serious or severe. HCRU was seldom reported. Overall, this review revealed a high variability in treatment patterns, limited availability of globally accepted standard of care treatments and disparate outcomes in countries in LATAM. Furthermore, we identified substantial gaps in the literature; filling these knowledge gaps in treatment utilization and outcomes may provide pathways to improving access for newer, more effective therapies, alleviating the substantial burden of MM in LATAM.